Abstracts tagged "Comorbidity"

Abstract Number: 0663 • ACR Convergence 2020
Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation
Nicholas Sumpter¹, Murray Cadzow², Alexander So³, Richard Reynolds¹ and Tony Merriman², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Otago, Dunedin, New Zealand, ³University of Lausanne, Lausanne, Switzerland
Background/Purpose: This study aimed to estimate the extent to which gout associated genetic variants are associated with the presence/absence of common comorbidities in gout patients…
Abstract Number: 1449 • ACR Convergence 2020
Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement
Alejandra Maria Patiño-Trives¹, Alejandro Ibáñez-Costa², Carlos Pérez-Sánchez¹, Laura Pérez-Sanchez³, Maria Luque-Tevar¹, Iván Arias de la Rosa¹, María-Carmen Abalos-Aguilera¹, Desirée Ruiz-Vilchez⁴, Pedro Segui⁵, Mario Espinosa⁵, Nuria Barbarroja¹, Eduardo Collantes⁴, Justo P. Castaño⁵, Raul M Luque⁵, María de los ángeles Aguirre-Zamorano⁵ and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba
Background/Purpose: To identify shared and differential changes in the splicing machinery of immune cells from antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome…
Abstract Number: 0177 • ACR Convergence 2020
Association of Hydroxychloroquine Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis
Nicholas Wiemer¹, Rebecca Schorr², Mary Chester Wasko³ and Tarun Sharma¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark, Pittsburgh, PA, ³Allegheny Health Network, West Penn Hospital, Pittsburgh, PA
Background/Purpose: Non-alcoholic fatty liver disease (NAFLD), the most common form of liver disease, refers to a spectrum of conditions which includes non-alcoholic fatty liver (NAFL),…
Abstract Number: 0678 • ACR Convergence 2020
Patient Characteristics and Patterns of Urate-lowering Treatments in Older Patients with Incident Gout
Kazuki Yoshida¹, Jun Liu², Daniel H Solomon³ and Seoyoung Kim³, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout is a common inflammatory arthritis caused by monosodium urate crystal deposition in the joints. Despite this well-understood pathophysiologic mechanism of disease and ACR and EULAR…
Abstract Number: 1466 • ACR Convergence 2020
Multimorbidity in Rheumatoid Arthritis, Psoriatic Arthritis, Gout, and Osteoarthritis Within the Rheumatology Informatics System for Effectiveness (RISE) Registry
Bryant England¹, Huifeng Yun², Lang Chen³, Kaleb Michaud¹, Ted Mikuls¹ and Jeffrey R Curtis², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rheumatic and musculoskeletal diseases (RMDs) often predispose the development of other chronic conditions, resulting in multimorbidity. While multimorbidity is increasingly being recognized and examined…
Abstract Number: 0178 • ACR Convergence 2020
Associations of Multimorbidity with DMARD Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry
Bryant England¹, Huifeng Yun², Lang Chen³, Kaleb Michaud¹, Ted Mikuls¹ and Jeffrey R Curtis², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although a treat-to-target strategy is endorsed in rheumatoid arthritis (RA) treatment guidelines, its routine implementation in real-world settings, particularly in the context of multimorbidity,…
Abstract Number: 0694 • ACR Convergence 2020
Relationships Among Adherence and Patient Outcomes in a Cognitive Behavioral Plus Physical Activity Intervention for Older Adults with Osteoarthritis and Hypertension
Xiaojun Shi¹, Elizabeth Schlenk² and Susan Sereika¹, ¹University of Pittsburgh School of Nursing, Pittsburgh, ²University of Pittsburgh School of Nursing, Pittsburgh, PA
Background/Purpose: Osteoarthritis of the knee (OAK) affects nearly 14 million older adults and more than half are diagnosed with hypertension (HTN). Cognitive behavior therapy (CBT)…
Abstract Number: 1472 • ACR Convergence 2020
Assessing Causal Associations of Urate Levels with Type 2 Diabetes and Related Glycemic Traits Using Bidirectional Mendelian Randomization
Natalie McCormick¹, Mark O'Connor¹, Shelby Marozoff², John Choi³, Aaron Leong¹ and Hyon Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, Canada, ³Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Type 2 diabetes (T2D) and gout/hyperuricemia frequently coexist, but the nature and direction of this relationship is unclear. Observational studies have reported positive associations…
Abstract Number: 0179 • ACR Convergence 2020
Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning
Bryant England¹, Yangyuna Yang¹, Punyasha Roul¹, Christian Haas², Lotfollah Najjar², Harlan Sayles¹, Fang Yu¹, Brian Sauer³, Joshua Baker⁴, Kaleb Michaud¹, Fenglong Xie⁵, Jeffrey R Curtis⁶ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Omaha, Omaha, NE, ³University of Utah, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Chronic conditions often complicate the disease course of rheumatoid arthritis (RA) and predispose to poor long-term outcomes. The interrelationship of individual chronic conditions and…
Abstract Number: 0881 • ACR Convergence 2020
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study
Irene van der Horst-Bruinsma¹, Rianne van Bentum¹, Frank Verbraak², Thomas Rath³, James Rosenbaum⁴, Bengt Hoepken⁵, Oscar Irvin-Sellers⁶, Thomas Kumke⁵, Lars Bauer⁵ and Martin Rudwaleit⁷, ¹Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ²Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³St Franziskus-Hospital, Münster, Germany, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1…
Abstract Number: 1607 • ACR Convergence 2020
Effectiveness of Dietary Counseling on Gout Management and Risk Factors for Metabolic Syndrome in Gout Patients
Juliana Chang¹, Jonathan Tsui² and Maida Wong³, ¹Division of Rheumatology, Department of Medicine, University of California Irvine, Irvine, CA, ²Geisinger Medical Center, Danville, PA, ³Division of Rheumatology, Department of Medicine, VA Long Beach Healthcare System, Long Beach, CA
Background/Purpose: Gout is the most prevalent inflammatory arthritis globally. Despite treatment advances, the prevalence of gout has continued to increase over the last several decades.…
Abstract Number: 0182 • ACR Convergence 2020
Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Spaethling-Mestekemper⁸, Christoph Kuhn⁹, Matthias Englbrecht¹⁰, Wolfgang Vorbrueggen¹¹ and Martin Welcker¹², ¹Rheumatology-Nephrology Practice, Erlangen, Germany, ²Department of Rheumatology, Internal Medicine, Rhein-Maas-Hospital, Wuerselen, Germany, ³Medical Centre Stolberg, Stolberg, Germany, ⁴Practice for Rheumatology and Internal Medicine, Berlin, Germany, ⁵Rheumatology-Nephrology Practice, Erlangen, ⁶Rheumatology Practice, Osnabrueck, ⁷Rheumatology Practice, Osnabrueck, Germany, ⁸Rheumatology Group Practice, Muenchen, Germany, ⁹Rheumatology Practice, Karlsruhe, ¹⁰Freelance Healthcare Data Scientist, Eckental, Germany, ¹¹Foundation for fostering rheumatology, Wuerselen, Germany, ¹²MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany
Background/Purpose: Patient registries have become a common approach to learn from patient-related data by prospectively including large numbers of individuals into a sample followed over…
Abstract Number: 0918 • ACR Convergence 2020
Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial
Kristin Highland¹, Gerard Criner², Petros Sfikakis³, Hilario Nunes⁴, Wendy Stevens⁵, Corinna Miede⁶, Margarida Alves⁷ and Michael Kreuter⁸, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ³National Kapodistrian University of Athens Medical School, Athens, Greece, ⁴Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, ⁵Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria, Australia, Fitzroy, Victoria, Australia, ⁶mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, Heidelberg, Germany
Background/Purpose: Gastroesophageal reflux disease (GERD) is a common comorbidity in patients with SSc-ILD and may be associated with progression of SSc-ILD. In the SENSCIS trial…
Abstract Number: 1657 • ACR Convergence 2020
Do Comorbidities Limit Improvement in Pain and Physical Function After Total Knee Arthroplasty in Patients with Knee Osteoarthritis?
Lauren King¹, Esther Waugh¹, Allyson Jones², Deborah Marshall³ and Gillian Hawker⁴, ¹University of Toronto, Toronto, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with knee osteoarthritis (OA) are increasingly living with multiple comorbid conditions. The presence of comorbidities has been associated with having worse OA symptoms…
Abstract Number: 0183 • ACR Convergence 2020
Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry
Toshihiro Matsui¹, Naonobu Sugiyama², Tsutomu Kawaguchi², Aosa Kamezaki², Shigeyuki Toyoizumi³, Fujio Matsuyama⁴, Tatsunori Murata⁴, Yukitomo Urata⁵, Kimito Kawahata⁶ and Shigeto Tohma⁷, ¹Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan, ²Pfizer Japan Inc, Tokyo, Japan, ³Pfizer R&D Japan G.K., Tokyo, Japan, ⁴CRECON Medical Assessment Inc, Tokyo, Japan, ⁵Department of Rheumatology, Tsugaru General Hospital, Aomori, Japan, ⁶Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: Patients (pts) with RA have an increased risk of some malignancies compared with the general population, and this can vary by region/race.1,2 Epidemiologic data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.